Simple Summary The majority of metastatic colorectal cancer cases are mismatch-repair-
proficient and microsatellite-stable, and unfortunately this condition is associated with an …

Although immunotherapy has revolutionized solid tumor treatment, durable responses in
gastric cancer (GC) remain limited. The heterogeneous tumor microenvironment (TME) …

CAMILLA is a basket trial (NCT03539822) evaluating cabozantinib plus the ICI durvalumab
in chemorefractory gastrointestinal cancer. Herein, are the phase II colorectal cohort results …

The success of immunotherapy for cancer treatment is limited by the presence of an
immunosuppressive tumor microenvironment (TME); Therefore, identifying novel targets to …

In 2023, colorectal cancer (CRC) is the third most diagnosed malignancy and the third
leading cause of cancer death worldwide. At the time of the initial visit, 20% of patients …

Background To determine whether the addition of durvalumab (anti-PD-L1) and oleclumab
(anti-CD73) to standard-of-care treatment (FOLFOX and bevacizumab) enhances the anti …

Gastric cancer (GC) is believed to be the fifth most common cancer and the third most
common cause of death worldwide. Treatment techniques include radiation, chemotherapy …

Anti-angiogenic agents elicit considerable immune modulatory effects within the tumor
microenvironment, underscoring the rationale for synergistic clinical development of VEGF …

Vascular endothelial growth factor inhibitors, including tyrosine kinase inhibitors (TKIs),
possess immunomodulatory properties and have shown promising outcomes when …

Colorectal cancer treatment has evolved considerably in the last decade with the
development of immunotherapies. Immune checkpoint inhibitor therapies have brisk and …